ATE481980T1 - Verfahren zur verabreichung eines thymosin-alpha 1 peptids - Google Patents

Verfahren zur verabreichung eines thymosin-alpha 1 peptids

Info

Publication number
ATE481980T1
ATE481980T1 AT02802520T AT02802520T ATE481980T1 AT E481980 T1 ATE481980 T1 AT E481980T1 AT 02802520 T AT02802520 T AT 02802520T AT 02802520 T AT02802520 T AT 02802520T AT E481980 T1 ATE481980 T1 AT E481980T1
Authority
AT
Austria
Prior art keywords
peptide
administration
alpha
thymosine
patient
Prior art date
Application number
AT02802520T
Other languages
English (en)
Inventor
Alfred Rudolph
Cynthia Tuthill
Original Assignee
Sciclone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE481980T1 publication Critical patent/ATE481980T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT02802520T 2001-11-01 2002-11-01 Verfahren zur verabreichung eines thymosin-alpha 1 peptids ATE481980T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33087401P 2001-11-01 2001-11-01
PCT/US2002/035093 WO2003037366A1 (en) 2001-11-01 2002-11-01 Method of administering a thymosin alpha 1 peptide

Publications (1)

Publication Number Publication Date
ATE481980T1 true ATE481980T1 (de) 2010-10-15

Family

ID=23291672

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02802520T ATE481980T1 (de) 2001-11-01 2002-11-01 Verfahren zur verabreichung eines thymosin-alpha 1 peptids

Country Status (19)

Country Link
US (2) US20050049191A1 (de)
EP (1) EP1450850B1 (de)
JP (1) JP2005511563A (de)
KR (1) KR20050042229A (de)
CN (1) CN1582163A (de)
AT (1) ATE481980T1 (de)
AU (1) AU2002363248B2 (de)
BR (1) BR0213823A (de)
CA (1) CA2464307A1 (de)
DE (1) DE60237784D1 (de)
EA (1) EA008536B1 (de)
ES (1) ES2353379T3 (de)
IL (2) IL161665A0 (de)
MX (1) MXPA04004187A (de)
NO (1) NO327101B1 (de)
NZ (1) NZ532763A (de)
PL (1) PL208388B1 (de)
UA (1) UA80957C2 (de)
WO (1) WO2003037366A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7897567B2 (en) * 2002-11-25 2011-03-01 Sciclone Pharmaceuticals, Inc. Methods of protecting against radiation damage using alpha thymosin
DK1613340T3 (da) * 2003-03-28 2010-08-30 Sciclone Pharmaceuticals Inc Behandling af aspergillus-infektioner med thymosin alfa 1
US8017129B2 (en) * 2006-06-15 2011-09-13 SciClone Pharmaceuticals International Ltd Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma
US20080300166A1 (en) * 2007-06-01 2008-12-04 Sciclone Pharmaceuticals, Inc. Treatment of Melanoma with Alpha Thymosin Peptides
AU2008338594A1 (en) * 2007-12-14 2009-06-25 Sciclone Pharmaceuticals, Inc. Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (HSAA)
WO2010129947A2 (en) 2009-05-08 2010-11-11 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
HK1207008A1 (en) * 2012-03-08 2016-01-22 Sciclone Pharmaceuticals, Inc. Use of thymosin alpha for treatment of purulent rhinosinusitis
US20130296223A1 (en) 2012-03-30 2013-11-07 Sciclone Pharmaceuticals, Inc. Use of thymosin alpha for the treatment of sepsis
JP6821560B2 (ja) * 2014-10-21 2021-01-27 サイクロン ファーマシューティカルズ インターナショナル エルティーディー．Ｓｃｉｃｌｏｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｔｄ． 免疫刺激剤による癌治療
AU2016217473B2 (en) * 2015-02-09 2021-07-29 Sciclone Pharmaceuticals International (Sg) Pte. Ltd. Thymosin alpha 1 for use in treatment of cystic fibrosis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) * 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4444757A (en) * 1981-11-16 1984-04-24 Research Corporation Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
TW224053B (de) * 1991-09-13 1994-05-21 Paul B Chretien
US5468729A (en) * 1993-10-26 1995-11-21 Alpha 1 Biomedicals Method for treatment of autoimmune hepatitis
US5760000A (en) * 1994-05-13 1998-06-02 University Technologies International,Inc. Inhibition of liver cancer by the use of GnRH and GnRH analogs
US5888980A (en) * 1994-06-30 1999-03-30 Bio-Logic Research And Development Corporation Compositions for enhancing immune function
US5632983A (en) * 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
US5849596A (en) * 1996-07-08 1998-12-15 Food Industry Research And Development Institute Process for determining the smoke content of edible oil
AU7788701A (en) * 2000-07-14 2002-01-30 Transform Pharmaceuticals Inc System and method for optimizing tissue barrier transfer of compounds
EP1343528A2 (de) * 2000-11-02 2003-09-17 Research Foundation of City University of New York Methoden zur stimulierung der regeneration und reparatur des nervensystems durch hemmung der phosphodiesterase typ 4

Also Published As

Publication number Publication date
EP1450850B1 (de) 2010-09-22
AU2002363248B2 (en) 2007-11-22
UA80957C2 (en) 2007-11-26
DE60237784D1 (de) 2010-11-04
EP1450850A1 (de) 2004-09-01
IL161665A0 (en) 2004-09-27
PL370430A1 (en) 2005-05-30
EA200400591A1 (ru) 2004-10-28
PL208388B1 (pl) 2011-04-29
CA2464307A1 (en) 2003-05-08
ES2353379T3 (es) 2011-03-01
EA008536B1 (ru) 2007-06-29
CN1582163A (zh) 2005-02-16
BR0213823A (pt) 2004-08-31
MXPA04004187A (es) 2004-07-08
NO20042100D0 (no) 2004-05-21
EP1450850A4 (de) 2005-11-30
WO2003037366A1 (en) 2003-05-08
IL161665A (en) 2011-03-31
US20100221274A1 (en) 2010-09-02
NO20042100L (no) 2004-05-21
KR20050042229A (ko) 2005-05-06
US20050049191A1 (en) 2005-03-03
NZ532763A (en) 2008-01-31
NO327101B1 (no) 2009-04-20
JP2005511563A (ja) 2005-04-28

Similar Documents

Publication Publication Date Title
MY132924A (en) Hematopoietic stimulation
CA2376978A1 (en) Compositions and methods for treatment of sexual dysfunction
EP1626055A3 (de) Nicht von Säugetieren stammende GnRH Analoga und deren Verwendung zur Regulierung des Immunsystems
DE60327843D1 (de) Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
MXPA05013340A (es) Composiciones y metodos para liberacion mucosal incrementada de la hormona del crecimiento.
ATE390142T1 (de) Synergistische zusammensetzung zur behandlung von diabetes mellitus
MXPA05006572A (es) Composiciones y metodos para la administracion mejorada por via mucosa de peptidos fijadores al receptor de y2 y metodos para tratar y prevenir la obesidad.
US12337065B2 (en) Compositions for treating viral infections and methods for same
DE60237784D1 (de) Verfahren zur verabreichung eines thymosin-alpha 1 peptids
SE8802569D0 (sv) Improvements in or relation to somatostatins
EA200400548A1 (ru) Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi)
DE60218193D1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
DE69615984D1 (de) Verwendung von Ursolsäure zur Herstellung eines Arzneimittels zur Unterdrückung von Metastasen
TR200101085T2 (tr) Kronik hepatit C enfeksiyonlu hastalarda algılanabilir HCV-RNA'nın yok edilmesi için birleşik ribavirin-interferon alfa tedavisi
ATE174794T1 (de) Parenteral anzuwendende aminosäuren enthaltende zubereitungen zur bekämpfung von hypotension und verwandten pathologien
ATE342276T1 (de) Nährstoffe aus sojabohnenprotein
ATE538782T1 (de) Modifizierte aminosaeure 5-cnac zur hemmung der thrombozytenaggregation
DE69834929D1 (de) Verwendung eines organspezifischen ernährungmittels
ATE420890T1 (de) Isoleucyl-valyl-threonyl-asparaginyl-threonyl- threonin (ivtntt) enthaltende biologisch wirksame peptide
EA201000501A1 (ru) Фармацевтическая композиция, содержащая не обладающий нейротоксичностью активатор плазминоген для лечения удара
DE602004007491D1 (de) Verfahren zur behandlung von leberkrebs durch intrahepatische verabreichung von nemorubicin
SE0200598D0 (sv) Pharmaceutical composition and method for treatment or prevention of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences
Binazzi Clinical and structural evaluation of the treatment of some hyperplastic and neoplastic skin diseases with 5-Fluorouracil (5-FU) ointment
RU2002113945A (ru) Способ создания "новокаиновой подушки" для микросклерозирования
RU2001104929A (ru) Способ лечения рассеянного склероза

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties